Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone*

  title={Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone*},
  author={Felicia C. Allen-Ramey and Leona E. Markson and Aylin Altan Riedel and Shiva G Sajjan and Kevin B. Weiss},
  journal={Current Medical Research and Opinion},
  pages={1453 - 1461}
ABSTRACT Objective: To examine the impact of controller monotherapy with montelukast or fluticasone on asthma-related health care resource use among children aged 2–14 years old. Design and methods: A retrospective claims-based analysis of asthmatic children, 2–14 years old, receiving a prescription (index) for montelukast or fluticasone between January 1, 1999 and June 30, 2000 was conducted. Children were matched by age and propensity score to obtain comparable treatment groups. The… Expand
Clinical and Economic Outcomes Associated with Low-Dose Fluticasone Propionate Versus Montelukast in Children with Asthma Aged 4 to 11 Years
Initiation of FP44 versus MON in children with asthma aged 4 to 11 years is associated with a significant reduction in asthma-related ED visits, costs, and oral corticosteroid use. Expand
Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors
The prescription of ICS monotherapy did not significantly reduce rescue oral corticosteroids or acute care visits and was associated with a higher rate of hospital admission for asthma and rescue β2-agonist use. Expand
Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids.
  • A. Wu, L. Li, +10 authors T. Lieu
  • Medicine
  • The journal of allergy and clinical immunology. In practice
  • 2014
Risks of asthma-related exacerbations did not differ between children who initiated LTRA and ICS, and these findings may be explainable by LTRA, which has similar effectiveness as ICS in real-life usage by residual confounding by indication or other unmeasured factors. Expand
Asthma costs and utilization in a managed care organization.
Total direct costs and asthma-related utilizations are meaningfully less in the year after being dispensed single controller ICS compared with single controller leukotriene modifiers or most combination controllers. Expand
Inhaled corticosteroids vs. leukotriene-receptor antagonists and asthma exacerbations in children.
ICS appears to be more frequently prescribed as an intermittent than a daily controller therapy resulting in less use, which may contribute to the apparent lower effectiveness compared to LTRA. Expand
Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
COPD patients' healthcare utilization and costs increased gradually over time, often with a marked increase in the month before COPD diagnosis, and more timely diagnosis and subsequent treatment may avoid costly Healthcare utilization and unnecessary mortality and morbidity post-diagnosis. Expand
Update on leukotriene receptor antagonists in preschool children wheezing disorders
The present review describes the most recent advances on the use of LTRAs in the treatment of preschool wheezing disorders and concludes that montelukast is a valid alternative to ICS especially in poorly compliant preschool children, or in subjects who show adverse effects related to long-term steroid therapy. Expand
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
The safety and efficacy of anti-leukotrienes compared to inhaled corticosteroids as monotherapy in adults and children with asthma is determined and better insight into the influence of patient and treatment characteristics on the magnitude of effects is provided. Expand
Ultrafine-Particle Inhalers, the Holy Grail of Inhaled Corticosteroid Therapy, or Not!
  • H. Kelly
  • Medicine
  • The journal of allergy and clinical immunology. In practice
  • 2015
The authors conclude that these results question the current asthma guidelines that recommend that children not responding to low-dose inhaled corticosteroid (ICS) therapy have long-acting b2 agonists added as preferential step-up therapy when simply switching to an ultrafineparticle ICS should be attempted first. Expand
Fenotipovi astme dječje dobi i kontrola bolesti u različitim dobnim skupinama
Astma je heterogena bolest koju cine razliciti fenotipovi s vjerojatno razlicitim, ali za sada nepoznatim uzrocima i prirodnim tijekom. Prospektivn


The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma.
In this open-label study, pediatric patients aged 2 to 5 years with mild to moderate persistent asthma receiving long-term therapy with montelukast had similar rates of asthma-related health care resource utilization compared with those receiving usual care with cromolyn or inhaled corticosteroids. Expand
Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Compared with montelukast-treated patients, patients treated with low-dose fluticasone propionate had a significantly lower risk of experiencing an asthma-related hospitalization, a lower riskof switching or augmenting with another controller, and significantly lower asthma and total health care costs. Expand
A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.
Montelukast patients had better adherence to their treatment regimen and required fewer beta-agonist prescriptions, which is an indicator of asthma control and possibly therapeutic effectiveness. Expand
Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.
Multivariate regression analysis indicated that compared to treatment with montelukast, treatment with FP had significantly (P<0.001) lower post-index total asthma related costs. Expand
Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data.
In this managed care population, patients treated with ICSs or LMs had similar measures of treatment effectiveness, as measured by asthma-related health care resource use. Expand
Asthma medication use and disease burden in children in a primary care population.
In this insured population of children with persistent asthma, inappropriate reliance on relievers and nonadherence to controllers were common and adequacy of asthma control was common. Expand
Outcomes of patients treated with fluticasone propionate or montelukast sodium.
In this managed care population of patients with asthma, fluticasone and montelukast provided similar effectiveness and use of a short-acting beta agonist (SABA) was significantly associated with flutic asone treatment. Expand
Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline.
Controller therapy significantly reduced the odds of postindex asthma-related hospitalizations and no significant difference was observed with asthma- related emergency department visits, and similar outcomes were observed in montelukast and fluticasone users. Expand
Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.
Montelukast effectively reduced asthma exacerbations in 2- to 5-year-old patients with intermittent asthma over 12 months of treatment and was generally well tolerated. Expand
Inadequate therapy for asthma among children in the United States.
Most children with moderate to severe asthma in this nationally representative sample, including those with multiple hospitalizations, did not receive adequate asthma therapy, and may incur avoidable morbidity. Expand